145 related articles for article (PubMed ID: 10566009)
1. BAY12-9566. BAY 12 9566, BAY12 9566.
Drugs R D; 1999 Feb; 1(2):142-3. PubMed ID: 10566009
[No Abstract] [Full Text] [Related]
2. AG 3340.
Drugs R D; 1999 Feb; 1(2):137-8. PubMed ID: 10566007
[No Abstract] [Full Text] [Related]
3. CGS 27023A. CDG 27023A.
Drugs R D; 1999 Feb; 1(2):144-5. PubMed ID: 10566010
[No Abstract] [Full Text] [Related]
4. AE 941--Neovastat.
Drugs R D; 1999 Feb; 1(2):135-6. PubMed ID: 10566006
[No Abstract] [Full Text] [Related]
5. Marimastat. BB 2516, TA 2516.
Drugs R D; 1999 Feb; 1(2):146-9. PubMed ID: 10566011
[No Abstract] [Full Text] [Related]
6. Batimastat. BB 94, collagenase inhibitors-1.
Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
[No Abstract] [Full Text] [Related]
7. Omapatrilat.
Drugs R D; 1999 Apr; 1(4):350-1. PubMed ID: 10566062
[No Abstract] [Full Text] [Related]
8. Endopeptidase inhibitors. Summary and table.
Coleman SG; Duff R
Drugs R D; 1999 Apr; 1(4):339-40. PubMed ID: 10566057
[No Abstract] [Full Text] [Related]
9. Clinical studies with matrix metalloproteinase inhibitors.
Brown PD
APMIS; 1999 Jan; 107(1):174-80. PubMed ID: 10190295
[TBL] [Abstract][Full Text] [Related]
10. New drugs on the horizon: matrix metalloproteinase inhibitors.
Rothenberg ML; Nelson AR; Hande KR
Stem Cells; 1999; 17(4):237-40. PubMed ID: 10437989
[No Abstract] [Full Text] [Related]
11. SCH 42495.
Drugs R D; 1999 Apr; 1(4):354-6. PubMed ID: 10566064
[No Abstract] [Full Text] [Related]
12. Candoxatrilat. UK 73967.
Drugs R D; 1999 Apr; 1(4):341-2. PubMed ID: 10566058
[No Abstract] [Full Text] [Related]
13. Ecadotril. (S)-acetorphan, sinorphan.
Drugs R D; 1999 Apr; 1(4):343-5. PubMed ID: 10566059
[No Abstract] [Full Text] [Related]
14. Inhibition of articular cartilage degradation in culture by a novel nonpeptidic matrix metalloproteinase inhibitor.
Billinghurst RC; O'Brien K; Poole AR; McIlwraith CW
Ann N Y Acad Sci; 1999 Jun; 878():594-7. PubMed ID: 10415783
[No Abstract] [Full Text] [Related]
15. Matrix metalloprotease inhibitors. Summary and Table.
Coleman SG
Drugs R D; 1999 Feb; 1(2):131-4. PubMed ID: 10566005
[No Abstract] [Full Text] [Related]
16. Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications.
Leff RL
Ann N Y Acad Sci; 1999 Jun; 878():201-7. PubMed ID: 10415731
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of angiogenesis enter phase III testing.
Nelson NJ
J Natl Cancer Inst; 1998 Jul; 90(13):960-3. PubMed ID: 9665141
[No Abstract] [Full Text] [Related]
18. Sampatrilat. UK 81252.
Drugs R D; 1999 Apr; 1(4):352-3. PubMed ID: 10566063
[No Abstract] [Full Text] [Related]
19. Development of matrix metalloproteinase inhibitors in cancer therapy.
Hidalgo M; Eckhardt SG
J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
[TBL] [Abstract][Full Text] [Related]
20. MDL 100240.
Drugs R D; 1999 Apr; 1(4):348-9. PubMed ID: 10566061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
